Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Arbor Biotechnologies

Main focus: Gene therapies and gene editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Primary Hyperoxaluria, undisclosed liver diseases

Genome editing tool: CRISPR-Cas13d, multiple novel CRISPR variants

Funding stage: Private

Location: Cambridge, MA, USA



Gene editing partnerships: Vertex Pharmaceuticals, Vor Biopharma

Arbor Biotechnologies is a CRISPR-focused company that develops novel Cas variants for enhanced precision and efficacy. The company's lead programme is being developed for primary hyperoxaluria. The company is co-founded by CRISPR pioneer Feng Zhang and has established multiple collaborations, including but not limited to Vertex Pharmaceuticals and Vor Biopharma.


HashtagArbor Biotechnologies

Company: Arbor Biotechnologies
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine